Clinical Advisors

Daniel D. Von Hoff, M.D., F.A.C.P. : Clinical Advisor

  • Mayo Clinic, TGen, US Oncology.
  • Physician in Chief, Distinguished Professor, Director of Clinical Translational Research Division at TGen;
  • CSO, US Oncology Research;
  • Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
  • Recognized expert in Oncology drug development;
  • PI on numerous phase I-III clinical trials including Abraxane; >620 papers, 137 book chapters
  • 2010 David A. Karnofsky Memorial Award from ASCO; Past President of the AACR; Appointed to President Bush’s National Cancer Advisory Board in 2004-2010.
  • Founder of ILEX™ Oncology.

Sant Chawla, MD, FRACP : Advisor, Oncology Programs

  • Director, Sarcoma Oncology Center, Santa Monica, CA.
  • Academic appointments and affiliations: Stanford Univ Medical Center, MD Anderson Cancer Center, David Geffen School of Medicine UCLA, Keck School of Medicine USC, Cedars Sinai Medical Center
  • Extensive Clinical trial experience (>30 yrs) : Phase 1-3. Pazopanib, Denosumab, Ridoforolimus (rapamycin analog), Palifosfomide, Aldoxorubicin, TH302, belinostat, ofatumumab, AMG655, MEK162 and others

James McKiernan, MD : Columbia University Medical Center

  • Chair, Department of Urology
  • John and Irene Given Professor of Urology, Herbert Irving Comprehensive Cancer Center
  • Recognized expert in treatment of early stage bladder cancer
  • PI, AADI Bladder cancer Phase I/II trial
  • > 130 publications
  • Investigator in numerous clinical trials

Mark Gladwin, MD : University of Pittsburgh School of Medicine [PAH]

  • Chief of the Pulmonary, Allergy and Critical Care Medicine Division
  • Recognized expert in pulmonary hypertension and sickle cell disease
  • PI, AADI Pulmonary Hypertension Phase I/II trial
  • > 200 publications
  • Investigator in > 25 clinical trials

Clinical Advisors

Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the completion of a $23 Million Series A round. The financing was led by Hermed Capital with participation from Celgene Corporation, Vivo Capital, Decheng Capital, the Helsinn Investment Fund and Star Summit Ventures. The company will use the capital to drive the clinical programs for ABI-009, its targeted albumin-bound mTOR inhibitor.

“We are extremely pleased with the participation and interest of our investors and now stand poised to develop the potential of what we believe is a best-in-class mTOR inhibitor,” said Neil Desai, Ph.D., Founder and CEO of Aadi.

Aadi is currently enrolling its registration trial for advanced Perivascular Epithelioid Cell tumors (PEComa), an extremely rare form of sarcoma. Aadi received agreement from the FDA on the design of its phase 2 registration study for the treatment of advanced PEComa with ABI-009. The study will enroll approximately 30-35 patients and the primary endpoint for the study is the overall response rate. Earlier this month, an independent data monitoring committee (DMC) reviewed the available data and concluded that the study should continue without modification.

Aadi’s other planned clinical programs include pulmonary hypertension (phase 1), early stage bladder cancer (phase 2) and pediatric cancers (phase 1). It continues to investigate applications of ABI-009 in cancer indications as well as cardiovascular and other diseases.

Dr. Desai is also pleased to welcome new directors to the board of Aadi including Carlo Montagner (Specialised Therapeutics), Richard Maroun (Frazier Healthcare Partners), Jerry Xiao (Hermed Capital) and Mahendra Shah (Vivo Capital).

About Aadi and ABI-009

Aadi is a clinical stage biopharmaceutical company led by Dr. Neil Desai, an inventor of ABRAXANE®, ABI-009 and the nab® technology platform. Aadi’s lead product is ABI-009, a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin. Aadi aims to develop the full potential of the albumin-bound mTOR inhibitor in diseases that are driven by mTOR activation and where the mTOR inhibitors have not or cannot be effectively exploited due to problems of effective drug delivery, safety or effective targeting to the disease site. In a phase 1 study ABI-009 was well tolerated at intravenous doses significantly higher than other mTOR inhibitors and its pharmacokinetic profile, with high Cmax and AUC, is very different from the approved mTOR inhibitors. In animal models, ABI-009 has greater antitumor efficacy than the oral mTOR inhibitors at the same dose. Similar to ABRAXANE®, albumin-bound rapamycin is expected to have high tumor penetration due to mechanisms of albumin uptake in tumors and other areas with tissue remodeling or inflammation. ABI-009 was licensed to Aadi in 2014 by Celgene Corporation (NASDAQ:CELG).

ABRAXANE® and nab® are registered trademarks of Celgene Corporation.